Decode Genetics' CEO, Kári Stefánsson, resigns from his position.
New Era Awaits DeCode Genetics After Kári Stefánsson's Departure
Kári Stefánsson, the Founder and longtime CEO of DeCode Genetics, has officially bid farewell to his reign at the groundbreaking Icelandic genetics firm he launched thirty years prior. This announcement signifies the end of an illustrious era for one of Iceland's most prominent scientific figures.
Taking the reins from Stefánsson now are Dr. Unnur Þorsteinsdóttir and Dr. Patrick Sulem, both esteemed researchers in the realm of Icelandic Genetics. Together, this dynamic duo will command the company's operations within Iceland.
Stefánsson's Decade-Long Legacy
Before passing the torch, Stefánsson, now 76 years old, established DeCode Genetics in 1996. Under his astute leadership, the company became a global frontrunner in human genetics research. In 2012, a U.S.-based pharmaceutical giant, Amgen, made headlines by acquiring DeCode Genetics, integrating its groundbreaking research into broader medical applications.
Expertised New Leaders
Dr. Unnur Þorsteinsdóttir entered DeCode Genetics in 2000 and most recently served as the company's Director of Genetic Research. She is also a professor at the University of Iceland's Faculty of Medicine and previously held the position of Dean of the School of Health Sciences from 2022 to 2024.
"The opportunity to contribute to research that placed Iceland on the world stage in human genetics has been an unparalleled privilege," she shared. "Genetics still holds endless mysteries, and I am as inspired today as I was on my very first day."
Dr. Patrick Sulem, a doctor with a background in epidemiology and public health, joined the company in 2002. With a history of managing DeCode's "Clinical Sequencing Project," Sulem has played a vital role in research that uncovers the genetic factors behind numerous diseases.
"I firmly believe in the potential of genetics to propel medical science forward," said Sulem. "Our commitment remains unwavering: turning scientific knowledge into real-world patient benefits."
Praising a Scientific Idealist
Jay Bradner, Amgen's Executive Vice President of Research and Development, lauded Stefánsson's significant influence in creating DeCode Genetics into a global leader in its field.
"Dr. Stefánsson's work has been instrumental in shaping Icelandic Genetics into a global powerhouse. We remain deeply appreciative of his contributions and continue to stand by Iceland as a pillar for cutting-edge genetic research," Bradner exclaimed.
In the domain of Icelandic Genetics, Dr. Unnur Þorsteinsdóttir and Dr. Patrick Sulem will carry on Stefánsson's legacy, leveraging technology to drive research in health-and-wellness and medical-conditions, as they continue to unveil the mysteries of genetics. With their combined expertise, they aim to transform scientific knowledge into tangible benefits for patients.
